Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 3/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021079 | 0.94 | GGPS1 (0.45) | GGPS1TOP2ASLC9A1DUTHCAR3 | |
| SCHEMBL13073400 | 0.93 | GGPS1 (0.47) | GGPS1TOP2ASLC9A1DUT | |
| SCHEMBL5021140 | 0.93 | GGPS1 (0.47) | GGPS1TOP2ASLC9A1DUT | |
| SCHEMBL5021145 | 0.93 | GGPS1 (0.47) | GGPS1TOP2ASLC9A1DUT | |
| SCHEMBL9926297 | 0.93 | GGPS1 (0.47) | GGPS1TOP2ASLC9A1DUT | |
| SCHEMBL9926336 | 0.92 | GGPS1 (0.51) | GGPS1TOP2ASLC9A1GRM2DUT | |
| SCHEMBL3546670 | 0.91 | GGPS1 (0.51) | GGPS1TOP2ASLC9A1GRM2DUT | |
| SCHEMBL17146870 | 0.89 | GGPS1 (0.53) | GGPS1TOP2ASLC9A1DUTALOX5 | |
| SCHEMBL10078113 | 0.89 | GGPS1 (0.53) | GGPS1TOP2ASLC9A1DUTALOX5 | |
| SCHEMBL9926332 | 0.89 | GGPS1 (0.53) | GGPS1TOP2ASLC9A1DUTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170247423-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | GGPS1 1733/4885TOP2A 1532/4885SLC9A1 3297/4885 |
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | GGPS1 1017/4885TOP2A 3664/4885SLC9A1 4796/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GGPS1 1228/4885TOP2A 2506/4885SLC9A1 4826/4885 |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | GGPS1 1581/4885TOP2A 4254/4885SLC9A1 4301/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GGPS1 1017/4885TOP2A 3664/4885SLC9A1 4796/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | GGPS1 2366/4885TOP2A 2918/4885SLC9A1 4816/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | GGPS1 2545/4885TOP2A 2180/4885SLC9A1 4254/4885 |
| US-20170247423-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | GGPS1 1297/4885TOP2A 3272/4885SLC9A1 3468/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | GGPS1 1414/4885TOP2A 3780/4885SLC9A1 4773/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GGPS1 1373/4885TOP2A 3123/4885SLC9A1 4318/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GGPS1 1228/4885TOP2A 2506/4885SLC9A1 4826/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | GGPS1 1228/4885TOP2A 2506/4885SLC9A1 4826/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GGPS1 2395/4885TOP2A 2744/4885SLC9A1 4041/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GGPS1 1248/4885TOP2A 972/4885SLC9A1 4605/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GGPS1 2395/4885TOP2A 2744/4885SLC9A1 4041/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | GGPS1 1106/4885TOP2A 3947/4885SLC9A1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.